MX356749B - Anticuerpo anti-homologo 4 de roundabout (robo4). - Google Patents
Anticuerpo anti-homologo 4 de roundabout (robo4).Info
- Publication number
- MX356749B MX356749B MX2014012351A MX2014012351A MX356749B MX 356749 B MX356749 B MX 356749B MX 2014012351 A MX2014012351 A MX 2014012351A MX 2014012351 A MX2014012351 A MX 2014012351A MX 356749 B MX356749 B MX 356749B
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- present disclosure
- angiogenesis
- rob04
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
Abstract
La presente invención se refiere a un anticuerpo que tiene una actividad anti-angiogénesis. Más específicamente, la presente invención se refiere a un anticuerpo contra ROBO4 y a una composición farmacéutica que contiene el anticuerpo. Un objeto de la presente invención es proporcionar un anticuerpo anti-ROBO4 que tiene un efecto anti-angiogénesis, una composición farmacéutica o similares que comprenden el anticuerpo, un método para suprimir angiogénesis usando el anticuerpo, etc. Otro objeto de la presente invención es proporcionar un método para producir el anticuerpo. El anticuerpo de la presente invención activa la señal descendente de ROBO4 y tiene una actividad supresora contra migración celular inducida por VEGF o bFGF. El anticuerpo de la presente invención también presenta un efecto anti-angiogénesis en modelos in-vivo. De esta manera, se ha resuelto el problema.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012103929A JP2013230115A (ja) | 2012-04-27 | 2012-04-27 | 抗ｒｏｂｏ４抗体 |
| JP2013011042A JP2014141434A (ja) | 2013-01-24 | 2013-01-24 | 抗ｒｏｂｏ４抗体 |
| PCT/IB2013/053312 WO2013160879A1 (en) | 2012-04-27 | 2013-04-26 | Anti-robo4-antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014012351A MX2014012351A (es) | 2015-01-12 |
| MX356749B true MX356749B (es) | 2018-06-12 |
Family
ID=48670623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014012351A MX356749B (es) | 2012-04-27 | 2013-04-26 | Anticuerpo anti-homologo 4 de roundabout (robo4). |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9683040B2 (es) |
| EP (1) | EP2841457B1 (es) |
| JP (2) | JP5897205B2 (es) |
| KR (2) | KR101950898B1 (es) |
| CN (1) | CN104768973B (es) |
| AU (1) | AU2013254313B2 (es) |
| BR (1) | BR112014026649A2 (es) |
| CA (1) | CA2868074A1 (es) |
| CO (1) | CO7111295A2 (es) |
| DK (1) | DK2841457T3 (es) |
| ES (1) | ES2733434T3 (es) |
| IN (1) | IN2014DN07799A (es) |
| MX (1) | MX356749B (es) |
| MY (1) | MY166821A (es) |
| NZ (1) | NZ629291A (es) |
| PH (1) | PH12014502382A1 (es) |
| PL (1) | PL2841457T3 (es) |
| RU (1) | RU2682451C2 (es) |
| SG (1) | SG11201405718QA (es) |
| TW (1) | TWI606065B (es) |
| WO (1) | WO2013160879A1 (es) |
| ZA (1) | ZA201406235B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9683040B2 (en) * | 2012-04-27 | 2017-06-20 | Daiichi Sankyo Company, Limited | Anti-ROBO4 antibody |
| PT3354729T (pt) | 2015-09-24 | 2024-04-11 | Daiichi Sankyo Co Ltd | Anticorpo anti-garp |
| JPWO2018070390A1 (ja) * | 2016-10-12 | 2019-08-22 | 第一三共株式会社 | 抗ｒｏｂｏ４抗体と他剤を含む組成物 |
| KR20210070643A (ko) | 2019-12-05 | 2021-06-15 | 김명배 | 자체 발전 웨어러블 다리 |
| US20250066471A1 (en) | 2022-02-16 | 2025-02-27 | Institut National de la Santé et de la Recherche Médicale | Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer |
| WO2025045139A1 (zh) * | 2023-08-31 | 2025-03-06 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别robo2的抗体及其应用 |
| CN117384290B (zh) * | 2023-12-11 | 2024-04-09 | 苏州因特药物研发有限公司 | 人源robo1结合分子及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| EP0656941B1 (en) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CN102311986B (zh) | 2000-10-06 | 2015-08-19 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| ATE360068T1 (de) * | 2000-11-06 | 2007-05-15 | Cancer Rec Tech Ltd | Bildgebende verfahren, diagnose und behandlung von krankheiten |
| JP4583638B2 (ja) | 2001-03-15 | 2010-11-17 | 独立行政法人科学技術振興機構 | アセチルリジン認識モノクローナル抗体及びその製造方法 |
| AU2003247828B2 (en) | 2002-06-27 | 2010-05-20 | University Of Utah Research Foundation | Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis |
| PT1565491E (pt) * | 2002-11-20 | 2010-07-06 | Cancer Rec Tech Ltd | ANTICORPOS QUE SE LIGAM AO ½CARROSSEL MáGICO (MR ½MAGIC ROUNDABOUT) HUMANO, SEUS POLIPéPTIDOS E SUAS UTILIZAÃES PARA INIBIÃO DA ANGIOGéNESE |
| MXPA05006724A (es) | 2003-01-07 | 2005-09-08 | Symphogen As | Metodo para producir proteinas policlonales recombinantes. |
| CN101600451A (zh) | 2006-12-11 | 2009-12-09 | 犹他大学研究基金会 | 用于治疗病理性血管生成和血管通透性的组合物和方法 |
| KR20090114443A (ko) | 2007-02-09 | 2009-11-03 | 제넨테크, 인크. | 항-Ｒｏｂｏ４ 항체 및 그의 용도 |
| TWI480050B (zh) * | 2009-02-10 | 2015-04-11 | Daiichi Sankyo Co Ltd | 抗－ｍｓｔ１ｒ抗體及其用途 |
| US9683040B2 (en) * | 2012-04-27 | 2017-06-20 | Daiichi Sankyo Company, Limited | Anti-ROBO4 antibody |
-
2013
- 2013-04-26 US US14/397,210 patent/US9683040B2/en not_active Expired - Fee Related
- 2013-04-26 PL PL13730645T patent/PL2841457T3/pl unknown
- 2013-04-26 JP JP2015507659A patent/JP5897205B2/ja not_active Expired - Fee Related
- 2013-04-26 MX MX2014012351A patent/MX356749B/es active IP Right Grant
- 2013-04-26 CN CN201380019999.8A patent/CN104768973B/zh not_active Expired - Fee Related
- 2013-04-26 RU RU2014147616A patent/RU2682451C2/ru not_active IP Right Cessation
- 2013-04-26 ES ES13730645T patent/ES2733434T3/es active Active
- 2013-04-26 CA CA2868074A patent/CA2868074A1/en not_active Abandoned
- 2013-04-26 BR BR112014026649A patent/BR112014026649A2/pt not_active Application Discontinuation
- 2013-04-26 AU AU2013254313A patent/AU2013254313B2/en not_active Ceased
- 2013-04-26 KR KR1020147029492A patent/KR101950898B1/ko not_active Expired - Fee Related
- 2013-04-26 TW TW102115219A patent/TWI606065B/zh not_active IP Right Cessation
- 2013-04-26 NZ NZ629291A patent/NZ629291A/en not_active IP Right Cessation
- 2013-04-26 MY MYPI2014703067A patent/MY166821A/en unknown
- 2013-04-26 DK DK13730645.2T patent/DK2841457T3/da active
- 2013-04-26 IN IN7799DEN2014 patent/IN2014DN07799A/en unknown
- 2013-04-26 EP EP13730645.2A patent/EP2841457B1/en active Active
- 2013-04-26 KR KR1020197004552A patent/KR20190020838A/ko not_active Ceased
- 2013-04-26 SG SG11201405718QA patent/SG11201405718QA/en unknown
- 2013-04-26 WO PCT/IB2013/053312 patent/WO2013160879A1/en not_active Ceased
-
2014
- 2014-08-25 ZA ZA2014/06235A patent/ZA201406235B/en unknown
- 2014-10-24 PH PH12014502382A patent/PH12014502382A1/en unknown
- 2014-10-27 CO CO14236457A patent/CO7111295A2/es unknown
-
2015
- 2015-12-11 US US14/966,292 patent/US9562096B2/en not_active Expired - Fee Related
-
2016
- 2016-03-01 JP JP2016038918A patent/JP6267733B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502382B1 (en) | Anti-robo4-antibody | |
| HUE049171T2 (hu) | Rák diagnózisban felhasználható Claudin 18.2 elleni antitestek | |
| ZA201600589B (en) | Enabling payments to be processed by only one merchant | |
| LT2895653T (lt) | Tirpios celiuliozės gamybos būdas, tirpi celiuliozė ir būdo panaudojimas | |
| AR091098A1 (es) | ANTICUERPOS E INMUNOCONJUGADOS CONTRA Ly6E Y METODOS DE USO | |
| WO2014197849A3 (en) | Anti-c10orf54 antibodies and uses thereof | |
| HRP20181302T1 (hr) | Terapija za obnavljanje mikrobiota (mrt), pripravci i postupci proizvodnje | |
| DK3041946T3 (da) | Fermentative production of oligosaccharides | |
| PL2828075T3 (pl) | Papier, drukarka, zastosowanie papieru do produkcji etykiet i sposoby wytwarzania papieru | |
| EP3008613A4 (en) | Determining message data to present | |
| MX2015010429A (es) | Cetuximab con glicosilación modificada y sus usos. | |
| PL2935595T3 (pl) | Sposób i urządzenie do wytwarzania biogazu z biomasy zawierającej lignocelulozę | |
| EP3581227C0 (en) | SYSTEM TO REDUCE LOCAL DISCOMFORT | |
| SG11201601468UA (en) | Catalyst for producing bio-based acrylic acid and its derivatives and the method for making thereof | |
| EP3031914A4 (en) | MODIFIED AMADORIASE AND METHOD FOR PRODUCING SAME, AGENT FOR IMPROVING SURFACTANT-RESISTANCE OF AMADORIASE AND COMPOSITION FOR MEASURING HbA1c USING SAME | |
| IN2014MN02114A (es) | ||
| EP3009008A4 (en) | CEREALS CONTAIN HERICIUM ERINACEUM AND PROCESS FOR THEIR PRODUCTION | |
| EP3049142A4 (en) | CATHETER ADDITIVE AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| FR2990216B1 (fr) | Reacteur pour la methanisation de la biomasse. | |
| SG11201506513RA (en) | Business lead generation system and method using structured social media content | |
| EP3088079A4 (en) | Catalyst for use in production of methyl methacrylate, and method for producing methyl methacrylate | |
| UY35795A (es) | Anticuerpos que neutralizan la actividad de dabigatran,etexilato de dabigatran y o-acilglucurónidos de dabigatran | |
| SI3064572T1 (sl) | Metoda za produkcijo inducirane pluripotentne izvorne celice iz mezenhimske izvorne celice in inducirana pluripotentna izvorna celica pridobljena z metodo | |
| ITSS20120008A1 (it) | "metodo per l'ossidazione selettiva del glicerolo a diidrossiacetone. | |
| TH1401006466A (th) | แผ่นเหล็กกล้าใช้ผลิตบรรจุภัณฑ์และวิธีการผลิตเพื่อการนั้น |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |